A detailed history of Private Portfolio Partners LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Private Portfolio Partners LLC holds 10,242 shares of ABBV stock, worth $2.09 Million. This represents 1.44% of its overall portfolio holdings.

Number of Shares
10,242
Previous 10,385 1.38%
Holding current value
$2.09 Million
Previous $1.89 Million 7.14%
% of portfolio
1.44%
Previous 0.4%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $22,134 - $25,848
-143 Reduced 1.38%
10,242 $1.76 Million
Q1 2024

May 09, 2024

SELL
$159.82 - $182.1 $40,434 - $46,071
-253 Reduced 2.38%
10,385 $1.89 Million
Q4 2023

Feb 07, 2024

BUY
$137.6 - $154.97 $5,916 - $6,663
43 Added 0.41%
10,638 $1.65 Million
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $31,393 - $36,342
-235 Reduced 2.17%
10,595 $1.58 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $12,058 - $15,005
-91 Reduced 0.83%
10,830 $1.46 Million
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $45,262 - $52,127
-313 Reduced 2.79%
10,921 $1.74 Million
Q4 2022

Feb 01, 2023

SELL
$138.31 - $165.87 $25,310 - $30,354
-183 Reduced 1.6%
11,234 $1.82 Million
Q3 2022

Mar 14, 2023

BUY
$134.21 - $153.93 $6,710 - $7,696
50 Added 0.44%
11,416 $1.53 Million
Q3 2022

Nov 07, 2022

BUY
$134.21 - $153.93 $6,710 - $7,696
50 Added 0.44%
11,417 $1.53 Million
Q2 2022

Mar 14, 2023

SELL
$137.62 - $174.96 $3,853 - $4,898
-28 Reduced 0.25%
11,366 $1.74 Million
Q2 2022

Aug 02, 2022

SELL
$137.62 - $174.96 $3,853 - $4,898
-28 Reduced 0.25%
11,367 $1.74 Million
Q1 2022

Mar 14, 2023

SELL
$131.98 - $163.75 $1,055 - $1,310
-8 Reduced 0.07%
11,394 $1.85 Million
Q1 2022

May 12, 2022

SELL
$131.98 - $163.75 $923 - $1,146
-7 Reduced 0.06%
11,395 $1.85 Million
Q4 2021

Mar 14, 2023

BUY
$107.43 - $135.93 $29,113 - $36,837
271 Added 2.43%
11,402 $1.54 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $29,113 - $36,837
271 Added 2.43%
11,402 $1.54 Million
Q3 2021

Mar 14, 2023

BUY
$106.4 - $120.78 $120,976 - $137,326
1,137 Added 11.38%
11,131 $1.2 Million
Q3 2021

Nov 04, 2021

BUY
$106.4 - $120.78 $120,870 - $137,206
1,136 Added 11.37%
11,131 $1.2 Million
Q2 2021

Mar 14, 2023

BUY
$105.21 - $117.21 $28,932 - $32,232
275 Added 2.83%
9,994 $1.13 Million
Q2 2021

Aug 11, 2021

BUY
$105.21 - $117.21 $29,037 - $32,349
276 Added 2.84%
9,995 $1.13 Million
Q1 2021

Mar 14, 2023

BUY
$102.3 - $112.62 $14,526 - $15,992
142 Added 1.48%
9,719 $1.05 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $14,424 - $15,879
141 Added 1.47%
9,719 $1.05 Million
Q4 2020

Mar 14, 2023

SELL
$80.49 - $108.67 $23,986 - $32,383
-298 Reduced 3.02%
9,577 $1.03 Million
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $23,905 - $32,274
-297 Reduced 3.01%
9,578 $1.03 Million
Q3 2020

Mar 14, 2023

SELL
$85.91 - $100.83 $116,751 - $137,027
-1,359 Reduced 12.1%
9,875 $864,000
Q3 2020

Nov 16, 2020

BUY
$85.91 - $100.83 $27,147 - $31,862
316 Added 3.31%
9,875 $865,000
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $152,536 - $204,116
2,079 Added 27.79%
9,559 $938,000
Q1 2020

May 14, 2020

SELL
$64.5 - $97.79 $24,768 - $37,551
-384 Reduced 4.88%
7,480 $570,000
Q4 2019

Feb 12, 2020

BUY
$72.13 - $90.25 $19,186 - $24,006
266 Added 3.5%
7,864 $696,000
Q3 2019

Nov 13, 2019

BUY
$62.98 - $75.72 $81,999 - $98,587
1,302 Added 20.68%
7,598 $576,000
Q2 2019

Aug 14, 2019

BUY
$65.7 - $83.98 $25,228 - $32,248
384 Added 6.5%
6,296 $458,000
Q1 2019

May 10, 2019

BUY
$77.14 - $90.79 $2,391 - $2,814
31 Added 0.53%
5,912 $477,000
Q4 2018

Feb 13, 2019

BUY
$77.85 - $96.01 $457,835 - $564,634
5,881 New
5,881 $542,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $360B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Private Portfolio Partners LLC Portfolio

Follow Private Portfolio Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Portfolio Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Portfolio Partners LLC with notifications on news.